HIV

Ongoing research is needed to further explore the best methods for anal cancer detection in people living with HIV, according to a recent review.

For someone with HIV, a mental health disorder may decrease their life expectancy by as many as five years, according to the results of a recent international study.

Sexual and gender minority individuals still face insurance denials and cost-sharing barriers when accessing pre-exposure prophylaxis (PrEP), despite having a Grade A recommendation from the United States Preventive Services Task Force (USPSTF).

HIV-fighting antibodies produced in infant macaques in a preclinical trial could be the future of HIV prevention in humans, according to Amir Ardeshir, Ph.D., DVM, Associate Professor of Microbiology and Immunology at Tulane University.

Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the importance of preexposure anaphylaxis and why he’s hesitant to jump on the Lenacapavir breakthrough bandwagon.

In this interview, Sarah Morris, chief product officer of Audere, explains why they chose to focus on women and young girls and how they have tailored their program to reach them.

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, according to the Merck news release.

Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?

More than 99% effective at preventing HIV in trials, Yeztugo (lenacapavir) is now the first and only twice-yearly option for pre-exposure prophylaxis (PrEP).

A new study found that implementing a specialty pharmacy program at St. Jude Children’s Research Hospital helped more young HIV patients achieve medication adherence and undetectable viral loads.

Although some HIV programs will remain, the proposed cuts in the fiscal year 2026 budget are too severe and will hinder HIV care and research in the United States, according to Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C.

The results feed into an effort to identify to monoclonal antibody combinations that would prevent and possibly treat HIV infections.

Almost half (48%) of HIV patients sometimes feel unheard by their healthcare providers, which highlights a need for increased disease awareness, according to the early results of a new ViiV Healthcare survey.

Previously used to treat HIV and Hepatitis B, nucleoside reverse transcriptase inhibitors (NRTIs) reduced the risk of Alzheimer’s disease by an average of 9% every year, according to new research published in Alzheimer’s and Dementia.

Medicaid is the main healthcare coverage for people living with HIV in the United States, according to data compiled by KFF.

In United States veterans, antiretroviral resistance was associated with higher healthcare resource utilization, despite lower pharmacy-related costs, according to an abstract submitted to the Academy of Managed Care Pharmacy (AMCP) held last week in Houston.

The Xpert MTB/Ultra molecular diagnostic test may become a viable option for detecting tuberculosis (TB) in the stool of adults with HIV, according to the results of a recent study.

The Centers for Disease Control and Prevention’s Division of HIV Prevention are a critical source of funding and outreach for states, according to Terri L. Wilder, MSW, HIV/Aging Policy Advocate at SAGE, an organization that serves LGBTQ+ elders.

The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the potential for extended dosing intervals.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded those from the twice-yearly dosing.

Prevalence varies by region and is impacted by social stigma, access to preventive medicine and a lack of HIV/AIDS education, according to new research published in Health Science Reports.

Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving this drug a priority review and expects to make a decision by June 19, 2025, according to a release.

The group released a statement today expressing that they are eager to work with Robert F. Kennedy Jr. to eradicate HIV when steps into his role as the Secretary of Health and Human Services.

Positive HIV status as well as socioeconomic disadvantages, not breastfeeding, are associated with infant length and birth weight, according to the results of a new South African study.

PEPFAR, the main U.S.-funded global AIDS program was given a waiver from the foreign aid freeze, but there is still uncertainty and interruptions, partly because many PEPFAR programs are implemented through USAID, which has been largely shutdown by the news administration.